BioVie Inc. Files S-1 Registration Statement

TL;DR

BioVie Inc. just filed an S-1, get ready for a potential public offering.

AI Summary

BioVie Inc. filed an S-1 registration statement with the SEC on November 21, 2024. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. The filing indicates its principal executive offices are located at 680 W Nye Lane, Suite 201, Carson City, NV 89703, with a contact phone number of 775-888-3162. Cuong Do is listed as the Chief Executive Officer.

Why It Matters

This S-1 filing is a crucial step for BioVie Inc. as it signals their intent to offer securities to the public, potentially raising capital for further development and operations.

Risk Assessment

Risk Level: medium — As an S-1 filing, it indicates a company is preparing to go public or conduct a secondary offering, which inherently carries market and execution risks.

Key Players & Entities

• BioVie Inc. (company) — Registrant
• NanoAntibiotics, Inc. (company) — Former company name
• Cuong Do (person) — Chief Executive Officer
• November 21, 2024 (date) — Filing date
• 680 W Nye Lane Suite 201 Carson City , NV 89703 (address) — Principal executive offices
• 775-888-3162 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.0001 — of the Class A common stock, par value $0.0001 per share (the "Common Stock"), of BioV
• $3.51 — ported on The Nasdaq Capital Market was $3.51 per share. Investing in these securiti
• $13.1 million — rant of a clinical trial award of up to $13.1 million from the U.S. Department of Defense ("D
• $12.6 million — r the Company to receive the additional $12.6 million of the aggregate $13.1 million in grant
• $5 billion — ening complications, generate more than $5 billion in annual treatment costs, and have an
• $10.00 — ering price to the March 4 Investors of $10.00 per share of Common Stock ("March 4 Sha
• $9.999 — ring price to the March 24 Investors of $9.999 per pre-funded warrant (the "March 4 Se
• $100 — ing, for an aggregate purchase price of $100.00, at an exercise price of $12.50 per
• $12.50 — ice of $100.00, at an exercise price of $12.50 per share, which is equal to 125% of th
• $1.53 — price to the September 23 Investors of $1.53 per share (the "September 23 Share Offe
• $1.5299 — blic offering price to the Investors of $1.5299 per pre-funded warrant (the "September
• $1.9125 — ice of $100.00, at an exercise price of $1.9125 per share, which is equal to 125% of th

Filing Documents

• bivi_s1.htm (S-1) — 275KB
• bivi_s1ex5z1.htm (EX-5.1) — 18KB
• bivi_s1ex23z1.htm (EX-23.1) — 2KB
• bivi_s1ex107.htm (EX-FILING FEES) — 30KB
• image_01.jpg (GRAPHIC) — 2KB
• image_02.jpg (GRAPHIC) — 22KB
• image_03.jpg (GRAPHIC) — 15KB
• 0001520138-24-000429.txt ( ) — 651KB
• bivi-20240930.xsd (EX-101.SCH) — 3KB
• bivi-20240930_def.xml (EX-101.DEF) — 29KB
• bivi-20240930_lab.xml (EX-101.LAB) — 36KB
• bivi-20240930_pre.xml (EX-101.PRE) — 26KB
• bivi_s1_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 10

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 11 SELLING STOCKHOLDERS 15 PLAN OF DISTRIBUTION 20 LEGAL MATTERS 22 EXPERTS 22 WHERE YOU CAN FIND MORE INFORMATION 22 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 22 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1, which we have filed with the Securities and Exchange Commission (the "SEC"), using a "shelf" registration process. Under this shelf registration process, the Selling Stockholders may from time to time sell the Shares described in this prospectus in one or more offerings or otherwise as described under "Plan of Distribution." This prospectus may be supplemented from time to time by one or more prospectus supplements. Such prospectus supplements may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you must rely on the information in the prospectus supplement. You should carefully read both this prospectus and any applicable prospectus supplement together with additional information described under the heading "Where You Can Find More Information" before deciding to invest in the Shares being offered. Neither we nor the Selling Stockholders have authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus or in any applicable prospectus supplement or any applicable free writing prospectus that we have authorized. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. The Shares are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information contained in or incorporated by reference in this prospectus is accurate as of any date other than the respective dates of such document. Our business, financial condition, results of operation

View Full Filing

View this S-1 filing on SEC EDGAR